NO20092421L - Substituerte isokinolin- og isokinolinonderivater som inhibitorer av RHO-kinase - Google Patents

Substituerte isokinolin- og isokinolinonderivater som inhibitorer av RHO-kinase

Info

Publication number: NO20092421L
Authority: NO; Norway
Prior art keywords: rho kinase; inhibitors; substituted isoquinoline; isoquinolinone derivatives; derivatives
Prior art date: 2006-12-27

Application number

NO20092421A

Other languages

English (en)

Norwegian (no)

Inventor

Armin Hofmeister

Oliver Plettenburg

Matthias Lohn

Joachim Brendel

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-27

Filing date

2009-06-25

Publication date

2009-09-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38191090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092421(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-25 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2009-09-17 Publication of NO20092421L publication Critical patent/NO20092421L/no

Links

102000000568 rho-Associated Kinases Human genes 0.000 title abstract 3
108010041788 rho-Associated Kinases Proteins 0.000 title abstract 3
VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
150000002537 isoquinolines Chemical class 0.000 title 1
-1 6-substituted isoquinoline Chemical class 0.000 abstract 1
102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 abstract 1
108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Emergency Medicine (AREA)

NO20092421A 2006-12-27 2009-06-25 Substituerte isokinolin- og isokinolinonderivater som inhibitorer av RHO-kinase NO20092421L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06026898		2006-12-27
PCT/EP2007/011163 WO2008077550A1 (en)	2006-12-27	2007-12-19	Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase

Publications (1)

Publication Number	Publication Date
NO20092421L true NO20092421L (no)	2009-09-17

Family

ID=38191090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092421A NO20092421L (no)	2006-12-27	2009-06-25	Substituerte isokinolin- og isokinolinonderivater som inhibitorer av RHO-kinase

Country Status (27)

Country	Link
US (2)	US8278294B2 (es)
EP (1)	EP2102187B1 (es)
JP (1)	JP5421783B2 (es)
KR (1)	KR101517154B1 (es)
CN (1)	CN101616909B (es)
AR (1)	AR064533A1 (es)
AU (1)	AU2007338406B2 (es)
BR (1)	BRPI0720862A2 (es)
CA (1)	CA2673916C (es)
CL (1)	CL2007003822A1 (es)
CO (1)	CO6321138A2 (es)
CR (1)	CR10812A (es)
DO (1)	DOP2009000163A (es)
EC (1)	ECSP099466A (es)
IL (1)	IL199541A (es)
MA (1)	MA31021B1 (es)
MX (1)	MX2009005825A (es)
MY (1)	MY150746A (es)
NI (1)	NI200900107A (es)
NO (1)	NO20092421L (es)
NZ (1)	NZ577981A (es)
RU (1)	RU2455302C2 (es)
TN (1)	TN2009000270A1 (es)
TW (1)	TWI435723B (es)
UY (1)	UY30840A1 (es)
WO (1)	WO2008077550A1 (es)
ZA (1)	ZA200903550B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007008926A1 (en)	2005-07-11	2007-01-18	Aerie Pharmaceuticals, Inc.	Isoquinoline compounds
WO2008036540A2 (en)	2006-09-20	2008-03-27	Boehringer Ingelheim International Gmbh	Rho kinase inhibitors
US8455513B2 (en)	2007-01-10	2013-06-04	Aerie Pharmaceuticals, Inc.	6-aminoisoquinoline compounds
US8455514B2 (en)	2008-01-17	2013-06-04	Aerie Pharmaceuticals, Inc.	6-and 7-amino isoquinoline compounds and methods for making and using the same
CA2726588C (en)	2008-06-03	2019-04-16	Karl Kossen	Compounds and methods for treating inflammatory and fibrotic disorders
PT2313374E (pt) *	2008-06-24	2013-11-29	Sanofi Sa	Isoquinolinas e isoquinolinonas 6-substituídas
CN102131784B (zh) *	2008-06-24	2014-08-27	赛诺菲-安万特	作为rho激酶抑制剂的取代的异喹啉和异喹啉酮
HRP20131040T1 (hr) *	2008-06-24	2013-12-06	Sanofi	Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze
US8450344B2 (en)	2008-07-25	2013-05-28	Aerie Pharmaceuticals, Inc.	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3053913B1 (en)	2009-05-01	2018-03-07	Aerie Pharmaceuticals, Inc.	Dual mechanism inhibitors for the treatment of disease
EP2729460B1 (en) *	2011-07-08	2016-01-13	Sanofi	Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
MX352295B (es)	2011-07-08	2017-11-17	Sanofi Sa	Compuestos de fenilo sustituidos.
JP2014518236A (ja) *	2011-07-08	2014-07-28	サノフイ	６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体
CN103160571A (zh) *	2011-12-09	2013-06-19	彩虹天健康科技研究(北京)有限责任公司	磷酸化肌球蛋白和驱动蛋白的激酶的发现
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
EP3141235A1 (en)	2012-12-06	2017-03-15	IP Gesellschaft für Management mbH	N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
DK3811943T3 (da)	2013-03-15	2023-04-03	Aerie Pharmaceuticals Inc	Forbindelse til anvendelse til behandling af øjenlidelser
EP3290407B1 (en)	2013-10-18	2020-01-01	Celgene Quanticel Research, Inc	Bromodomain inhibitors
FR3017868A1 (fr)	2014-02-21	2015-08-28	Servier Lab	Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
ES2735087T3 (es)	2014-12-24	2019-12-16	Gilead Sciences Inc	Compuestos de pirimidina fusionados para el tratamiento de VIH
BR112017013440A2 (pt)	2014-12-24	2018-01-09	Gilead Sciences, Inc.	compostos de isoquinolina para o tratamento de hiv
TWI699355B (zh)	2014-12-24	2020-07-21	美商基利科學股份有限公司	喹唑啉化合物
AR104259A1 (es)	2015-04-15	2017-07-05	Celgene Quanticel Res Inc	Inhibidores de bromodominio
US10550087B2 (en)	2015-11-17	2020-02-04	Aerie Pharmaceuticals, Inc.	Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en)	2015-11-17	2017-05-09	Aerie Pharmaceuticals, Inc.	Process for the preparation of kinase inhibitors and intermediates thereof
AU2017252276A1 (en)	2016-04-18	2018-11-15	Celgene Quanticel Research, Inc.	Therapeutic compounds
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
KR102568079B1 (ko)	2016-08-31	2023-08-17	에어리 파마슈티컬즈, 인코포레이티드	안과용 조성물
EP3509588B1 (en) *	2016-09-12	2023-06-07	Integral Health,Inc.	Bicyclic compounds useful as gpr120 modulators
WO2018049324A1 (en)	2016-09-12	2018-03-15	Numerate, Inc.	Monocyclic compounds useful as gpr120 modulators
KR20190135027A (ko)	2017-03-31	2019-12-05	에어리 파마슈티컬즈, 인코포레이티드	아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
TWI834634B (zh) *	2018-02-02	2024-03-11	美商建南德克公司	醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法
AU2019337703B2 (en)	2018-09-14	2023-02-02	Aerie Pharmaceuticals, Inc.	Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109180586B (zh) *	2018-10-10	2022-03-08	成都理工大学	作为Rho激酶抑制剂的六氢氮杂卓-4-基氧基苯甲酰胺类化合物
TW202136261A (zh)	2018-10-31	2021-10-01	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
TWI721623B (zh)	2018-10-31	2021-03-11	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en)	2019-05-23	2022-09-27	Gilead Sciences, Inc.	Substituted eneoxindoles and uses thereof
WO2022046158A1 (en) *	2020-08-27	2022-03-03	Woolsey Pharmaceuticals, Inc	Methods of treating age-related cognitive decline
WO2023076812A1 (en)	2021-10-30	2023-05-04	Aneuryst, Inc.	Treatments for disturbed cerebral homeostasis
EP4431596A4 (en)	2021-11-11	2026-01-14	The Doshisha	CRYOCONSERVATION PREPARATION FOR CORNIAL ENDOTHELIAL CELLS AND PROCESS FOR PRODUCING SAID CRYOCONSERVATION PREPARATION

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2485537B2 (fr)	1977-04-13	1986-05-16	Anvar	Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja)	1990-07-31	1994-03-03	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	選択されたハロカーボンの触媒平衡化
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en)	1995-08-15	1995-10-18	Zeneca Ltd	Medicament
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ513800A (en)	1996-08-12	2001-09-28	Welfide Corp	Treatment of diseases using Rho kinase inhibitors
JPH1087629A (ja)	1996-09-18	1998-04-07	Fujisawa Pharmaceut Co Ltd	新規イソキノリン誘導体、およびその医薬用途
JP2001514259A (ja)	1997-08-29	2001-09-11	ゼネカ・リミテッド	アミノメチルオキソオキサゾリジニルベンゼン誘導体
TW575567B (en) *	1998-10-23	2004-02-11	Akzo Nobel Nv	Serine protease inhibitor
GB9912701D0 (en)	1999-06-01	1999-08-04	Smithkline Beecham Plc	Novel compounds
US6541456B1 (en)	1999-12-01	2003-04-01	Isis Pharmaceuticals, Inc.	Antimicrobial 2-deoxystreptamine compounds
IL150650A0 (en)	2000-01-20	2003-02-12	Eisai Co Ltd	Piperidine derivatives and pharmaceutical compositions containing the same
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (en)	2000-02-29	2001-09-07	Curis, Inc.	Methods and compositions for regulating adipocytes
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en)	2000-05-31	2000-07-19	Astrazeneca Ab	Chemical compounds
WO2002034712A1 (en)	2000-10-27	2002-05-02	Takeda Chemical Industries, Ltd.	Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (en)	2001-01-15	2002-07-18	Glaxo Group Limited	Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv)	2001-03-23	2001-03-23	Astrazeneca Ab	Novel compounds
WO2002088101A2 (en)	2001-04-27	2002-11-07	Vertex Pharmaceuticals Incorporated	Inhibitors of bace
JPWO2002100833A1 (ja)	2001-06-12	2004-09-24	住友製薬株式会社	Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
WO2003024450A1 (en)	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methods for treating prion diseases
SE0104340D0 (sv)	2001-12-20	2001-12-20	Astrazeneca Ab	New compounds
AU2003281623B8 (en) *	2002-07-22	2009-06-11	Asahi Kasei Pharma Corporation	5-substituted isoquinoline derivative
EP1550660A1 (en)	2002-09-12	2005-07-06	Kirin Beer Kabushiki Kaisha	Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
PL378754A1 (pl) *	2003-03-03	2006-05-15	F.Hoffmann-La Roche Ag	2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6
WO2004105757A2 (en)	2003-05-29	2004-12-09	Schering Aktiengesellschaft	Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EP1638939A2 (en)	2003-06-24	2006-03-29	Neurosearch A/S	Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2005030791A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Isoquinolinone potassium channel inhibitors
JP4794446B2 (ja)	2003-09-23	2011-10-19	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリン系カリウムチャンネル阻害薬
US20050067037A1 (en)	2003-09-30	2005-03-31	Conocophillips Company	Collapse resistant composite riser
JPWO2005035516A1 (ja)	2003-10-10	2006-12-21	小野薬品工業株式会社	新規縮合複素環化合物およびその用途
WO2005054202A1 (en)	2003-11-25	2005-06-16	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
JP2005232175A (ja) *	2004-01-21	2005-09-02	Asahi Kasei Pharma Kk	５−置換イソキノリン医薬
WO2005074535A2 (en)	2004-01-30	2005-08-18	Eisai Co., Ltd.	Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en)	2004-03-05	2008-09-03	Eisai Co Ltd	TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
SE0400850D0 (sv)	2004-03-30	2004-03-31	Astrazeneca Ab	Novel Compounds
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
NZ565040A (en) *	2005-06-28	2010-05-28	Sanofi Aventis	Isoquinoline derivatives as inhibitors of RHO-kinase
JP5049970B2 (ja)	2005-07-26	2012-10-17	サノフイ	Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
KR101373535B1 (ko) *	2005-07-26	2014-03-12	사노피	Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
TW200745101A (en)	2005-09-30	2007-12-16	Organon Nv	9-Azabicyclo[3.3.1]nonane derivatives
US7618985B2 (en) *	2005-12-08	2009-11-17	N.V. Organon	Isoquinoline derivatives
TW200738682A (en) *	2005-12-08	2007-10-16	Organon Nv	Isoquinoline derivatives
US7893088B2 (en)	2006-08-18	2011-02-22	N.V. Organon	6-substituted isoquinoline derivatives
RU2468011C2 (ru)	2006-12-27	2012-11-27	Санофи-Авентис	Замещенные циклоалкиламином производные изохинолина и изохинолинона
WO2008077555A2 (en)	2006-12-27	2008-07-03	Sanofi-Aventis	Substituted isoquinolines and their use as rho-kinase inhibitors

2007
- 2007-12-19 RU RU2009128645/04A patent/RU2455302C2/ru not_active IP Right Cessation
- 2007-12-19 CA CA2673916A patent/CA2673916C/en not_active Expired - Fee Related
- 2007-12-19 EP EP07856886.2A patent/EP2102187B1/en active Active
- 2007-12-19 MX MX2009005825A patent/MX2009005825A/es active IP Right Grant
- 2007-12-19 MY MYPI20092506 patent/MY150746A/en unknown
- 2007-12-19 JP JP2009543371A patent/JP5421783B2/ja not_active Expired - Fee Related
- 2007-12-19 CN CN2007800485477A patent/CN101616909B/zh not_active Expired - Fee Related
- 2007-12-19 KR KR1020097013514A patent/KR101517154B1/ko not_active Expired - Fee Related
- 2007-12-19 BR BRPI0720862-6A patent/BRPI0720862A2/pt not_active IP Right Cessation
- 2007-12-19 NZ NZ577981A patent/NZ577981A/en not_active IP Right Cessation
- 2007-12-19 WO PCT/EP2007/011163 patent/WO2008077550A1/en not_active Ceased
- 2007-12-19 AU AU2007338406A patent/AU2007338406B2/en not_active Ceased
- 2007-12-25 TW TW096149805A patent/TWI435723B/zh not_active IP Right Cessation
- 2007-12-26 UY UY30840A patent/UY30840A1/es unknown
- 2007-12-26 AR ARP070105900A patent/AR064533A1/es unknown
- 2007-12-26 CL CL2007003822A patent/CL2007003822A1/es unknown
2009
- 2009-05-20 CR CR10812A patent/CR10812A/es not_active Application Discontinuation
- 2009-05-22 ZA ZA200903550A patent/ZA200903550B/xx unknown
- 2009-06-01 NI NI200900107A patent/NI200900107A/es unknown
- 2009-06-16 CO CO09062104A patent/CO6321138A2/es active IP Right Grant
- 2009-06-18 US US12/487,403 patent/US8278294B2/en not_active Expired - Fee Related
- 2009-06-24 IL IL199541A patent/IL199541A/en active IP Right Grant
- 2009-06-24 MA MA32035A patent/MA31021B1/fr unknown
- 2009-06-25 TN TNP2009000270A patent/TN2009000270A1/fr unknown
- 2009-06-25 NO NO20092421A patent/NO20092421L/no not_active Application Discontinuation
- 2009-06-26 DO DO2009000163A patent/DOP2009000163A/es unknown
- 2009-06-26 EC EC2009009466A patent/ECSP099466A/es unknown
2012
- 2012-08-15 US US13/586,468 patent/US8461144B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NI200900107A (es)	2010-01-15
DOP2009000163A (es)	2009-08-31
US20100063025A1 (en)	2010-03-11
JP5421783B2 (ja)	2014-02-19
EP2102187A1 (en)	2009-09-23
AU2007338406B2 (en)	2012-08-09
BRPI0720862A2 (pt)	2014-02-25
ECSP099466A (es)	2009-07-31
US8278294B2 (en)	2012-10-02
ZA200903550B (en)	2010-04-28
IL199541A (en)	2014-08-31
KR101517154B1 (ko)	2015-04-30
EP2102187B1 (en)	2015-04-01
CO6321138A2 (es)	2011-09-20
US8461144B2 (en)	2013-06-11
CA2673916A1 (en)	2008-07-03
AU2007338406A1 (en)	2008-07-03
MA31021B1 (fr)	2009-12-01
NZ577981A (en)	2011-12-22
US20120316152A1 (en)	2012-12-13
CN101616909A (zh)	2009-12-30
MY150746A (en)	2014-02-28
CR10812A (es)	2009-08-12
UY30840A1 (es)	2008-07-31
TWI435723B (zh)	2014-05-01
RU2009128645A (ru)	2011-02-10
HK1140201A1 (en)	2010-10-08
JP2010514715A (ja)	2010-05-06
WO2008077550A1 (en)	2008-07-03
CL2007003822A1 (es)	2009-10-16
KR20090094337A (ko)	2009-09-04
CN101616909B (zh)	2013-09-11
CA2673916C (en)	2015-02-17
MX2009005825A (es)	2009-06-16
RU2455302C2 (ru)	2012-07-10
TN2009000270A1 (en)	2010-10-18
AR064533A1 (es)	2009-04-08
TW200848043A (en)	2008-12-16

Legal Events

Date	Code	Title	Description
2017-07-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20092421L (no)	2009-09-17	Substituerte isokinolin- og isokinolinonderivater som inhibitorer av RHO-kinase
NO20092434L (no)	2009-09-23	Nye substituerte isokinolin- og isokinolinonderivater
NO20092488L (no)	2009-09-22	Cykloalkylaminsubstituerte isokinolin- og isokinolinonderivater
NO20092424L (no)	2009-09-18	Substituerte isokinolin- og isokinolinonderivater
NO20092422L (no)	2009-09-25	Cykloalkylaminsubstituerte isokinolonderivater
DK2125744T3 (da)	2011-08-01	Cycloalkylaminsubstituerede isochinolon- og isochinolinonderivater
ATE554072T1 (de)	2012-05-15	Cycloalkylaminsubstituierte isochinolinderivate
TNSN08039A1 (en)	2009-07-14	Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
NO20080965L (no)	2008-02-22	Cykloheksylaminisokinolonderivater som Rho-kinaseinhibotorer
MY146037A (en)	2012-06-15	Isoquinoline derivatives as inhibitors of rho-kinase
MY157330A (en)	2016-05-31	Substituted isoquinolinones as rho kinase inhibitors
MY153615A (en)	2015-02-27	6-substituted isoquinolines and isoquinolinones
NO20080419L (no)	2008-01-22	Isokinolinderivater som inhibitorer av Rho-kinase
NI201000217A (es)	2011-05-24	Quinolinas e isoquinolinas 6 - sustituidas.
TN2010000589A1 (en)	2012-05-24	Substituted dsoquinolines and isoquinodlinones as rho kinase inhibitors